治疗相关急性淋巴细胞白血病是具不良遗传特征和临床结局的独立实体
该回顾性多中心研究比较了治疗相关急性淋巴细胞白血病(t-ALL,n=116)、原发急性淋巴细胞白血病(dn-ALL,n=100)及有既往恶性肿瘤史但未接受细胞毒治疗(pm-ALL,n=20)的患者,发现t-ALL患者从首次恶性肿瘤到ALL诊断的间隔更短、不良风险细胞遗传学特征频率更高,且中位总生存期显著短于dn-ALL或pm-ALL患者,支持t-ALL为独立实体。
要点
- t-ALL患者较pm-ALL患者具有更短的首发恶性肿瘤至ALL诊断间隔及更高频率的不良细胞遗传学特征。
- t-ALL患者中位总生存期显著短于dn-ALL或pm-ALL患者。
- 符合造血干细胞移植条件的t-ALL患者长期生存改善。
核心结论
- t-ALL基于其生物学和临床特征应被视为一个独立实体。
研究设计与样本
- 回顾性多中心研究,纳入t-ALL患者116例、dn-ALL患者100例、pm-ALL患者20例。
主要发现
- 与pm-ALL患者相比,t-ALL患者从首次恶性肿瘤到ALL诊断的间隔显著更短,且不良风险细胞遗传学特征(如KMT2A重排和骨髓增生异常综合征样异常,例如单体核型)频率更高。
- t-ALL患者中观察到多种突变,多数患者携带更常见于髓系恶性肿瘤的突变(如DNMT3A、RUNX1、ASXL1),其他患者携带ALL型突变(如CDKN2A、IKZF1)。
- t-ALL队列的中位总生存期显著短于dn-ALL或pm-ALL患者。
- 符合造血干细胞移植条件的患者长期生存改善。
临床怎么用
- t-ALL患者应被识别为具有不良遗传特征和较差预后的独立亚群。
- 对于符合条件的t-ALL患者,应考虑造血干细胞移植以改善长期生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with therapy-related acute lymphoblastic leukemia (t-ALL) represent a small subset of acute lymphoblastic leukemia (ALL) patients who received genotoxic therapy (ie, chemotherapy or radiation) for a prior malignancy. These patients should be distinguished from patients with de novo ALL (dn-ALL) and ALL patients who have a history of prior malignancy but have not received cytotoxic therapies in the past (acute lymphoblastic leukemia with prior malignancy [pm-ALL]). We report a retrospective multi-institutional study of patients with t-ALL (n = 116), dn-ALL (n = 100), and pm-ALL (n = 20) to investigate the impact of prior cytotoxic therapies on clinical outcomes. Compared with patients with pm-ALL, t-ALL patients had a significantly shorter interval between the first malignancy and ALL diagnosis and a higher frequency of poor-risk cytogenetic features, including KMT2A rearrangements and myelodysplastic syndrome-like abnormalities (eg, monosomal karyotype). We observed a variety of mutations among t-ALL patients, with the majority of patients exhibiting mutations that were more common with myeloid malignancies (eg, DNMT3A, RUNX1, ASXL1), whereas others had ALL-type mutations (eg, CDKN2A, IKZF1). Median overall survival was significantly shorter in the t-ALL cohort compared with patients with dn-ALL or pm-ALL. Patients who were eligible for hematopoietic cell transplantation had improved long-term survival. Collectively, our results support t-ALL as a distinct entity based on its biologic and clinical features.
引用
- Saygin C, Kishtagari A, Cassaday RD, et al. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019. PMID: 31869410. doi:10.1182/bloodadvances.2019000925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。